Identification of 10 differently expressed lncRNAs as prognostic biomarkers for prostate adenocarcinoma

Ziyu Wu; Sugui Wang; Qiang Li; Qingsong Zhao; Mingming Shao; Ziyu Wu; Sugui Wang; Qiang Li; Qingsong Zhao; Mingming Shao

doi:10.3934/mbe.2020108

Mathematical Biosciences and Engineering

2020, Volume 17, Issue 3: 2037-2047. doi: 10.3934/mbe.2020108

Previous Article Next Article

Research article Special Issues

Identification of 10 differently expressed lncRNAs as prognostic biomarkers for prostate adenocarcinoma

1.
Department of Urology, Huai’an Hospital Affiliated of Xuzhou Medical University, 62 South Huaihai Road, Huai’an 223002, China
2.
Department of Urology, Jining NO.1 People’s hospital, 6 Jiankang Road, Jining 272000, China
3.
Department of Urology, Jining NO.1 People’s hospital, 99 Shixian Road, Jining High-tech Zone, Jining 272000, China

Received: 19 April 2019 Accepted: 05 September 2019 Published: 24 December 2019

Prostate adenocarcinoma (PRAD) is one of the most frequently diagnosed cancer in males. Previous studies had demonstrated long non-coding RNAs (lncRNAs) played crucial roles in human cancers. In present study, we reported ten disease-free survival time related lncRNAs in PRAD, including RP11-468E2.5, GS1-393G12.13, CTD-2228K2.7, RP11-783K16.13, RP11-631N16.4, CTC-435M10.12, RP11-1109F11.5, RP11-228B15.4, RP11-496I9.1, and RP11-95O2.5. Higher expression of these lncRNAs significantly correlates to shorter DFS time in patients with PRAD. We next constructed lncRNAs regulating PPI networks in PRAD. Bioinformatics analysis revealed these DFS-related lncRNAs were associated with the regulation of cell cycle, glucose metabolic process, histone modification, and RNA splicing. AR and SPOP were identified to be involved in regulating these lncRNAs expression in PRAD. The prognostic value and molecular functions of these lnRNAs in human diseases remained largely unknown. We thought this study for the first time demonstrated that they could act as novel potential biomarkers for PRAD.
- biomarker,
- key lncRNA,
- prostate cancer,
- PPI network,
- co-expression networks
Citation: Ziyu Wu, Sugui Wang, Qiang Li, Qingsong Zhao, Mingming Shao. Identification of 10 differently expressed lncRNAs as prognostic biomarkers for prostate adenocarcinoma[J]. Mathematical Biosciences and Engineering, 2020, 17(3): 2037-2047. doi: 10.3934/mbe.2020108

Related Papers:

Abstract

Prostate adenocarcinoma (PRAD) is one of the most frequently diagnosed cancer in males. Previous studies had demonstrated long non-coding RNAs (lncRNAs) played crucial roles in human cancers. In present study, we reported ten disease-free survival time related lncRNAs in PRAD, including RP11-468E2.5, GS1-393G12.13, CTD-2228K2.7, RP11-783K16.13, RP11-631N16.4, CTC-435M10.12, RP11-1109F11.5, RP11-228B15.4, RP11-496I9.1, and RP11-95O2.5. Higher expression of these lncRNAs significantly correlates to shorter DFS time in patients with PRAD. We next constructed lncRNAs regulating PPI networks in PRAD. Bioinformatics analysis revealed these DFS-related lncRNAs were associated with the regulation of cell cycle, glucose metabolic process, histone modification, and RNA splicing. AR and SPOP were identified to be involved in regulating these lncRNAs expression in PRAD. The prognostic value and molecular functions of these lnRNAs in human diseases remained largely unknown. We thought this study for the first time demonstrated that they could act as novel potential biomarkers for PRAD.

References

[1]	X. Z. Wang, J. R. Beebe, L. Pwiti, A. Bielawska, M. J. Smyth, Aberrant sphingolipid signaling is involved in the resistance of prostate cancer cell lines to chemotherapy, Cancer Res., 59 (1999), 5842-5848.
[2]	K. E. Richert-Boe, L. L. Humphrey, A. G. Glass, N. S. Weiss, Screening digital rectal examination and prostate cancer mortality: A case-control study, J. Med. Screening, 5 (1998), 99-103.
[3]	W. Zhou, Z. Tao, Z. Wang, W. Hu, M. Shen, L. Zhou, et al., Long noncoding RNA PCA3 gene promoter region is related to the risk of prostate cancer on Chinese males, Exp. Mol. Pathol., 97 (2014), 550-553.
[4]	C. Haldrup, A. L. Pedersen, N. Øgaard, S. H. Strand, S. Høyer, M. Borre, et al., Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies, Mol. Oncol., 12 (2018), 545-560.
[5]	L. J. Fan, H. J. Han, J. Guan, X. W. Zhang, Q. H. Cui, H. Shen, et al., Aberrantly expressed long noncoding RNAs in recurrent implantation failure: A microarray related study, Syst. Biol. Reprod. Med., 63 (2017), 269-278.
[6]	L. Deng, S. B. Yang, F. F. Xu, J. H. Zhang, Long noncoding RNA CCAT1 promotes hepatocellular carcinoma progression by functioning as let-7 sponge, J. Exp. Clin. Cancer Res., 34 (2015), 18.
[7]	D. Chakravarty, A. Sboner, S. S. Nair, E. Giannopoulou, R. Li, S. Hennig, et al., The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer, Nat. Communi., 5 (2014), 5383.
[8]	W. C. Cui, Y. F. Wu, H. M. Qu, Up-regulation of long non-coding RNA PCAT-1 correlates with tumor progression and poor prognosis in gastric cancer, Eur. Rev. Med. Pharmacol. Sci., 21 (2017), 3021-3027.
[9]	W. H. Shi, Q. Q. Wu, S. Q. Li, T. X. Yang, Z. H. Liu, Y. S. Tong, et al., Upregulation of the long noncoding RNA PCAT-1 correlates with advanced clinical stage and poor prognosis in esophageal squamous carcinoma, Tumour Biol., 36 (2015), 2501-2507.
[10]	X. Wan, W. Huang, S. Yang, Y. Zhang, H. Pu, F. Fu, et al., Identification of androgen-responsive lncRNAs as diagnostic and prognostic markers for prostate cancer, Oncotarget, 7 (2016), 60503-60518.
[11]	K. Tomczak, P. Czerwinska, M. Wiznerowicz, The Cancer Genome Atlas (TCGA): An immeasurable source of knowledge, Contemp. Oncol., 19 (2015), A68-A77.
[12]	J. Du, Z. Yuan, Z. Ma, J. Song, X. Xie, Y. Chen, KEGG-PATH: Kyoto encyclopedia of genes and genomes-based pathway analysis using a path analysis model, Mol. Biosyst., 10 (2014), 2441-2447.
[13]	Z. Tang, C. Li, B. Kang, G. Gao, C. Li, Z. Zhang, GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses, Nucleic Acids Res., 45 (2017), W98-W102.
[14]	Z. Zhou, Z. Dai, S. Zhou, Z. Hu, Q. Chen, Y. Zhao, et al., HNRNPAB induces epithelial-mesenchymal transition and promotes metastasis of hepatocellular carcinoma by transcriptionally activating SNAIL, Cancer Res., 74 (2014), 2750-2762.
[15]	Y. Zhang, S. Pitchiaya, M. Cieślik, Y. S. Niknafs, J. Tien, Y. Hosono, et al., Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression, Nat. Genet., 50 (2018), 814-824.
[16]	F. F. Coelho, F. L. Guimarã£Es, W. L. Cabral, P. G. Salles, E. C. Mateo, L. M. N. Nogueita, et al., Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer, Genet. Mol. Res., 14 (2015), 13519-13531.
[17]	C. Huang, W. Yu, Q. Wang, H. Cui, Y. Wang, L. Zhang, et al., Increased expression of the lncRNA PVT1 is associated with poor prognosis in pancreatic cancer patients, Minerva Med., 106 (2015), 143-149.
[18]	M. Wu, X. Li, C. K. Kwoh, S. K. Ng, A core-attachment based method to detect protein complexes in PPI networks, BMC Bioinf., 10 (2009), 169.
[19]	F. Lan, R. E. Colins, R. De Cegli, R. Alpatov, J. R. Horton, X. Shi, et al., Recognition of unmethylated histone H3 lysine 4 links BHC80 to LSD1-mediated gene repression, Nature, 448 (2007), 718-722.
[20]	H. Takeuchi, S. Ozawa, N. Ando, C. H. Shih, K. Koyanagi, M. U. Ozawa, et al., Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 3 (1997), 2229-2236.
[21]	E. S. Antonarakis, AR Signaling in Human Malignancies: Prostate Cancer and Beyond, Cancers, 9 (2017), 7.
[22]	T. Ken-Ichi, K. Horie-Inoue, S. Katayama, T. Suzuki, S. Tsutsumi, K. Ikeda, et al., Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer, EMB J., 32 (2013), 1665-1680.
[23]	W. Huang, X. Su, W. Yan, Z. Kong, D. Wang, Y. Huang, et al., Overexpression of AR-regulated lncRNA TMPO-AS1 correlates with tumor progression and poor prognosis in prostate cancer, Prostate, 78 (2018), 1248-1261.
[24]	M. Yan, H. Qi, J. Li, G. Ye, Y. Shao, T. Li, et al., Identification of SPOP related metabolic pathways in prostate cancer, Oncotarget, 8 (2017), 103032-103046.

Reader Comments

Your name:*

Email:*
© 2020 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)